Physician profile
Robert E Breving
NPI 1003887217
$1,448.29
in general payments reported to CMS, 2019-2025
26 companies · $13.49 in 2025
The $13.49 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $166 · 2021: $722 · 2022: $172 · 2023: $97.47 · 2025: $13.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $110.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Centinel Spine, LLC | $606.66 | 2021 | |
| Acera Surgical, INC. | $106.90 | 2019-2021 | |
| Kci USA, INC. | $64.04 | 2019-2021 | |
| Covidien Lp | $59.94 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $59.25 | 2022-2023 | Dupixent |
| Merck Sharp & Dohme LLC | $51.03 | 2022-2023 | Zinplava, Dificid |
| Kerecis Limited | $49.47 | 2020-2022 | |
| Smith+Nephew, INC. | $44.33 | 2019 | |
| Abbvie INC. | $40.53 | 2022-2023 | Qulipta |
| Davol INC. | $37.07 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $36.51 | 2022-2023 | Rytary |
| Olympus America INC. | $34.66 | 2019 | |
| Innocoll Pharmaceuticals Limited | $33.68 | 2021-2022 | |
| Amgen INC. | $23.93 | 2020 | |
| Ethicon US, LLC | $21.55 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bolder Surgical LLC | $20.06 | 2020 | |
| Midsouth Orthopedics INC. | $19.71 | 2022 | |
| Boston Scientific Corporation | $18.99 | 2021 | |
| Osiris Therapeutics INC. | $17.91 | 2019 | |
| Acell, INC. | $17.58 | 2020 | |
| Alexion Pharmaceuticals, INC. | $16.33 | 2021 | |
| Mauna Kea Technologies, INC. | $15.76 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.86 | 2023 | Plenvu, Xifaxan |
| Exelixis INC. | $13.49 | 2025 | Cabometyx |
| Allergan, INC. | $12.71 | 2020 | |
| Travere Therapeutics, INC. | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Breving listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.